CD8A and neoplasm: We and others recently demonstrated that the PI3Kδ-selective inhibitor PI-3065, reduces the expansion and suppressive capacity of Tregs, conferring CD8+ T-cell-mediated tumour control in the 4T1 mouse model of breast cancer [17, 18].